drugset / Trial / NCT02209714
Safety, Tolerability and Pharmacodynamics After Oral Administration of BIIF 1149 BS in Healthy Male Volunteers
RandomizedParallel-groupDouble-blindTreatment
Summary
The objective of the study is to obtain information about the safety and tolerability of BIIF 1149 BS45 (single dose: 40, 65, 100 mg), to determine the pharmacologically active dose (range) by performing a citric acid challenge test and to obtain preliminary pharmacokinetic data.
Timeline
- Start
- 1999-11
- Primary completion
- 2000-02
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | FIGOPITANT | Small molecule | 40 mg | Oral |
| Subject | FIGOPITANT | Small molecule | 65 mg | Oral |
| Subject | FIGOPITANT | Small molecule | 100 mg | Oral |
Indications
No indication recorded.